PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine.

@article{Rosenblatt2011PD1BB,
  title={PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine.},
  author={Jacalyn M Rosenblatt and Brett E Glotzbecker and Heidi Mills and Baldev Vasir and Dimitrios Tzachanis and James D. Levine and Robin M. Joyce and Kerry Wellenstein and Whitney Keefe and Michael Schickler and Rinat Rotem-Yehudar and Donald Kufe and David Avigan},
  journal={Journal of immunotherapy},
  year={2011},
  volume={34 5},
  pages={409-18}
}
We have developed a cancer vaccine in which autologous tumor is fused with dendritic cells (DCs) resulting in the presentation of tumor antigens in the context of DC-mediated costimulation. In clinical trials, immunologic responses have been observed, however responses may be muted by inhibitory pathways. The PD1/PDL1 pathway is an important element contributing to tumor-mediated immune suppression. In this study, we demonstrate that myeloma cells and DC/tumor fusions strongly express PD-L1… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
106 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 106 extracted citations

Similar Papers

Loading similar papers…